The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression;A glutamáterg neurotranszmisszió "szomorú" vetülete: Az NMDA-receptor antagonisták mint új terápiás lehetőségek a major depresszió kezelésében

Neuropsychopharmacologia Hungarica

Volumn 14, Issue 1, 2012, Pages 29-40

  Szakács, Réka ^a   Janka, Zoltán ^a   Kálmán, János ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Antidepressant; Depression; Glutamatergic neurotransmission; Mood disorders; NMDA antagonists

Indexed keywords

AMANTADINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

DISEASE SEVERITY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; GLUTAMATERGIC NEUROTRANSMISSION; MAJOR DEPRESSION; MOOD DISORDER; NEUROTRANSMISSION; RECEPTOR AFFINITY; REVIEW;

EID: 84862888215     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: 10.5706/nph201203003     Document Type: Review

References (77)

1. Angst, J., Angst, F., Stassen, H.H. (1999) Suicide risk in patients with major depressive disorder. J Clin Psychiatry, 60 (suppl. 2): 57-62.
2. Angst, J., Cui, L., Swendsen, J., Rothen, S., Cravchik, A., Kessler, R.C., Merikangas, K.R. (2010) Major depressive disorder with subthreshold bipolarity in the national comorbidity survey replication. Am J Psychiatry, 167: 1194-1201.
3. Bekkers, J.M., Stevens, C.F. (1989) NMDA and non-NMDA receptors are co-localized at individual excitatory synapses in cultured rat hippocampus. Nature, 341: 230-233.
4. Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., Krystalm, J.H. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 47: 351-354.
5. Bremner, J.D., Narayan, M., Anderson, E.R., Staib, L.H., Miller, H.L., Charney, D.S. (2000) Hippocampal volume reduction in major depression. Am J Psychiatry, 157: 115-118.
6. Bremner, J., Vythilingam, M., Vermetten, E., Nazeer, A., Adil, J., Khan, S., Staib, L.H, Charney, D.S. (2002) Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry, 15: 273-279.
7. Cameron, H.A., McEwen, B.S., Gould, E. (1995) Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus. J Neurosci, 15: 4687-4692.
8. Carlisle, H.J., Kennedy, M.B. (2005) Spine architecture and synaptic plasticity. Trends Neurosci, 28: 182-187.
9. Coyle, J.T., Schwarcz, R. (2000) Mind glue: Implications of glial cell biology for psychiatry. Arch Gen Psychiatry, 57: 90-93.
10. Crane, G.E. (1959) Cycloserine as an antidepressant agent. Am J Psychiatry, 115: 1025-1026.
11. Crane, G.E. (1961) The psychotropic effects of cycloserine: a new use for an antibiotic. Compr Psychiatry, 2: 51-59.
12. Danysz, W., Parsons, C.G., Komhuber, J., Schmidt, W.J., Quack, G. (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci Biobehav Rev, 21: 455-468.
13. Dietrich, D.E., Bode, L., Spannhuth, C.W., Lau, T., Huber, T.J., Brodhun, B., Ludwig, H., Emrich, H.M. (2000) Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord, 2: 65-70.
14. Drevets, W.C. (2001) Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol, 11: 240-249.
15. Duman, R.S., Malberg, J., Thome, J. (1999) Neural plasticity to stress and antidepressant treatment. Biol Psychiatry, 46: 1181- 1191.
16. Fagiolini, A., Kupfer, D.J., Masalehdan, A., Scott, J.A., Houck, P.R. (2005) Functional impairment in the remission phase of bipolar disorder. Bipolar Disord, 7: 281-285.
17. Faludi, G., Gonda, X., Kliment, E., Bekes, V., Meszaros, V., Olah, A. (2010) Development of Depression Profile: a new psychometric instrument to selectively evaluate depressive symptoms based on the neurocircuitry theory. Neuropsychopharmacol Hung, 12(2): 337-345.
18. Fava, M., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Alpert, J.E., McGrath, P.J., Thase, M.E., Warden, D., Biggs, M.M., Luther, J.F., Niderehe, G., Ritz, L., Trivedi, M.H. (2006) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry, 163: 1161-1172.
19. Freund, T.F., Buzsáki, G. (1996) Interneurons of the hippocampus. Hippocampus, 6: 347-470.
20. Ghaemi, S.N., Rosenquist, K.J., Ko, J.Y., Baldassano, C.F., Kontos, N.J., Baldessarini, R.J. (2004) Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry, 161: 163-165.
21. Gould, E., Tanapat, P. (1999) Stress and hippocampal neurogenesis. Biol Psychiatry, 46: 1472-1479.
22. Heresco-Levy, U., Javitt, D.C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., Kremer, I. (2006) Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord, 93: 239-43.
23. Huber, T.J., Dietrich, D.E., Emrich, H.M. (1999) Possible use of amantadine in depression. Pharmacopsychiatry, 32: 47-55.
24. Kasai, H., Fukuda, M., Watanabe, S., Hayashi-Takagi, A., Noguchi, J. (2010) Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci, 33: 121-129.
25. Keck, P.E. Jr., Kessler, R.C., Ross, R. (2008) Clinical and economical effects of unrecognized or inadequately treated bipolar disorder. J Psychiatr Pract, 14 (suppl. 2): 31-38.
26. Kojima, N., Shirao, T. (2007) Synaptic dysfunction and disruption of postsynaptic drebrin-actin complex: A study of neurological disorders accompanied by cognitive deficits. Neurosci Res, 58: 1-5.
27. Koukopoulos, A., Reginaldi, D., Serra, G., Koukopoulos, A., Sani, G., Serra, G. (2010) Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord, 12: 348-349.
28. Kovacs, T. (2009) Therapy of Alzheimer disease. Neuropsychopharmacol Hung, 11(1): 27-33.
29. Lai, T., Payne, M.E., Byrum, C.E., Steffens, D.C., Krishnan, K.R. (2000) Reduction of orbital frontal cortex volume in geriatric depression. Biol Psychiatry, 48: 971-975.
30. Lopes, T., Neubauer, P., Boje, K.M. (1997) Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test. Pharmacol Biochem Behav, 58: 1059-1064.
31. Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T., Murray, C.J. (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet, 367: 1747-1757.
32. MacMaster, F.P., Mirza, Y., Szeszko, P.R., Kmiecik, L.E., Easter, P.C., Taormina, S.P., Lynch, M., Rose, M., Moore, G.J., Rosenberg, D.R. (2008) Amygdala and hippocampal volumes in familial early onset major depressive disorder. Biol Psychiatry, 63: 385-390.
33. Maeng, S., Zarate, C.A. Jr. (2007) The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep, 9: 467-474.
34. Maj, J., Rogoz, Z., Skuza, G., Wedzony, K. (1996) The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. J Neural Transm, 103: 131-146.
35. Manji, H.K., Quiroz, J.A., Sporn, J., Payne, J.L., Denicoff, K., Gray, N.A., Zarate, C.A. Jr., Charney, D.S. (2003) Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry, 53: 707-742.
36. Mattson, M.P. (2008) Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci, 1144: 97-112.
37. Matus, A. (2000) Actin-based plasticity in dendritic spines. Science, 290: 754-758.
38. McEwen, B.S. (2001) Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci, 933: 265-277.
39. Mervaala, E., Fohr, J., Kohoonen, M.,Valkonen-Korhonen, M., Vainio, P., Partanen, K., Partanen, J., Tiihonen, J., Viinamäki, H., Karjalainen, A.K., Lehtonen, J. (2000) Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol Med, 30: 117-125.
40. Molnar, E., Isaac, J.T. (2002) Developmental and activity dependent regulation of ionotropic glutamate receptors at synapses. ScientificWorldJournal, 2: 27-47.
41. Moryl, E., Danysz, W., Quack, G. (1993) Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol, 72: 394-397.
42. Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J., Monteggia, L.M. (2002) Neurobiology of depression. Neuron, 34: 13-25.
43. O'Donovan, C., Garnham, J.S., Hajek, T., Alda, M. (2008) Antidepressant monotherapy in pre-bipolar depression; predictive value and inherent risk. J Affect Disord, 107: 293-298.
44. Padovan, C.M., Guimarães, F.S. (2004) Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats. Pharmacol Biochem Behav, 77: 15-19.
45. Papp, M., Moryl, E. (1993) New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Pol J Pharmacol, 45: 549-553.
46. Papp, M., Moryl, E. (1996) Antidepressant-like effects of 1-aminocyclopropanecarbxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol, 316: 145-151.
47. Parsons, C.G., Panchenko, V.A., Pinchenko, V.O., Tsyndrenko, A.Y., Krishtal, O.A. (1996) Comparative patch clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci, 8: 446-454.
48. Parsons, C.G., Danysz, W., Quack, G. (1999) Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology, 38: 735-767.
49. Payne, J.L., Quiroz, J.A., Zarate, C.A. Jr., Manji, H.K. (2002) Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol Psychiatry, 52: 921-926.
50. Redmond, A.M., Kelly, J.P., Leonard, B.E. (1997) Behavioural and neurochemical effects of dizocilpine in the olfactory bul bectomized rat model of depression. Pharmacol Biochem Behav, 58: 355-359.
51. Reijnders, J.S., Ehrt, U., Weber, W.E., Aarsland, D., Leentjens, A.F. (2008) A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord, 23: 183-189.
52. Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., Möbius, H.J. (2003) Memantine in moderate-to-severe Alzheimer's disease. N Eng J Med, 348: 1333-1341.
53. Rihmer, Z., Kiss, K. (2002) Bipolar disorders and suicidal behaviour. Bipolar Disord, 4 (Suppl. 1): 21-25.
54. Rihmer, Z., Akiskal H. (2006) Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord, 94: 3-13.
55. Rihmer, A., Gonda, X., Balazs, J., Faludi, G. (2008) The importance of depressive mixed states in suicidal behavior. Neuropsychopharmacol Hung, 10 (1): 45-49.
56. Rihmer, Z., Gonda, X. (2011) Antidepressant-resistant depression and antidepressant-associated suicidal behaviour: the role of underlying bipolarity. Depress Res Treat, 2011: 906462.
57. Rogoz, Z., Skuza, G., Maj, J., Danysz, W. (2002) Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swim test in rats. Neuropharmacology, 42: 1024-1030.
58. Sapolsky, R.M. (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry, 57: 925-935.
59. Sen, S., Sanacora, G. (2008) Major depression: emerging therapeutics. Mt Sinai J Med, 75: 204-225.
60. Shah, P.J., Ebmeier, K.P., Glabus, M.F., Goodwin, G.M. (1998) Cortical grey matter reductions associated with treatmentresistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry, 172: 527-532.
61. Sheline, Y.I., Wang, P.W., Gado, M.H., Csernansky, J.G., Vannier, M.W. (1996) Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA, 93: 3908-3913.
62. Sheline, Y.I., Gado, M.H., Price, J.L. (1998) Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport, 9: 2023-2028.
63. Sheline, Y.I., Sanghavi, M., Mintun, M.A., Gado, M.H. (1999) Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci, 19: 5034-5043.
64. Skolnick, P., Legutko, B., Li, X., Bymaster, F.P. (2001) Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res, 43: 411-423.
65. Szakacs, R., Weiczner, R., Mihaly, A., Krisztin-Peva, B., Zador, Z., Zador, E. (2003) Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex. Brain Res Bull, 59: 485-493.
66. Tada, T., Sheng, M. (2006) Molecular mechanisms of dendritic spine morphogenesis. Curr Opin Neurobiol, 16: 95-101.
67. Tohen, M., Hennen, J., Zarate, C.M. Jr., Baldessarini, R.J., Strakowski, S.M., Stoll, A.L., Faedda, G.L., Suppes, T., Gebre- Mehdin, P., Cohen, B.M. (2000) Two-year syndromal and functional recovery in 219 cases of first episode major affective disorder with psychotic features. Am J Psychiatry, 157: 220-228.
68. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasubramani, G.K., Fava, M., STAR*D study team. (2006) Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: implications for clinical practice. Am J Psychiatry, 163: 28-40.
69. Trullas, R., Skolnick, P. (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol, 185: 1-10.
70. Ullian, E.M., Sapperstein, S.K., Christopherson, K.S., Barres, B.A. (2001) Control of synapse number by glia. Science, 291: 657-661.
71. Vakili, K., Pillay, S.S., Lafer, B., Fava, M., Renshaw, P.F., Bonello-Cintron, C.M., Yurgelun-Todd, D.A. (2000) Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol Psychiatry, 47: 1087-1090.
72. Wenthold, R.J., Roche, K.W. (1998) The organization and regulation of non-NMDA receptors in neurons. In: Ottersen, O.P, Langmoen, I.A., Gjerstad, L. (Eds.), Progress in Brain Research, Vol. 116, The Glutamate Synapse as a Therapeutical Target: Molecular Organization and Pathology of the Glutamate Synapse. Elsevier, Amsterdam, pp. 133-152.
73. Wooley, C.S., Weiland, N.G., McEwen, B.S., Schwartzkroin, P. A. (1997) Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J Neurosci, 17: 1848-1859.
74. Woo, Y.S., Chae, J.H., Yun, T.Y., Kim, K.S., Bahk, W.M. (2008) The bipolar diathesis of treatment-resistant major depressive disorder. Int J Psychiatry Clin Pract, 12: 142-146.
75. Zarate, C.A., Quiroz, J., Payne, J., Manji, H.K. (2002) Modulators of the glutamatergic system: Implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull, 36: 35-83.
76. Zarate, C.A. Jr., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, N., Luckenbaugh, D.A., Charney, D.S., Manji, H.K. (2006) A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 63: 856-864.
77. Zarate, C.A. Jr., Singh, J.B., Quiroz, J.A., De Jesus G., Denicoff, K.K., Luckenbaugh, D.A., Manji, H.K., Charney, D.S. (2006) A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry, 163: 153-155.